Paclitaxel in breast cancer

Oncologist

Volumn 3, Issue 6, 1998, Pages 373-389

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antineoplastic agents; Breast neoplasms; Clinical trials; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0032437869     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-6-373     Document Type: Article

References (20)

1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259.
2. Mamounas E, Brown A, Fisher B et al. 3-hour(hr) high dose taxol (T) infusion in advanced breast cancer (ABC): an NSAPB phase II study. Proc Am Soc Clin Oncol 1995;14:127.
3. Seidman AD, Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-2581.
4. Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 1996;23(suppl 11):6-10.
5. Holmes FA, Valero V, Walters RS et al. The M.D. Anderson Cancer Center experience with taxol in metastatic breast cancer. J Natl Cancer Inst Monogr 1993;15:161-169.
6. Abrams JS, Vena DA, Baltz J et al. Paclitaxel activity in heavily pretreated breast cancer; a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13:2056-2065.
7. Seidman AD, Reichman BS, Crown JP et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-1159.
8. Fountzilas G, Athanassiades A, Giannakakia T et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996;32:47-51a.
9. Nabholtz JM, Gelmon K, Bontebal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1867.
10. Winer E, Berry D, Dugan D et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Proc Am Soc Clin Oncol 1998;17:101a.
11. Mamounas E, Brown A, Smith R et al. Effect of the taxol duration of infusion in advanced breast cancer (ABC): results from NSAPB B-26 trial comparing 3- to 24-hr infusion of high dose taxol. Proc Am Soc Clin Oncol 1998;17:101a.
12. Holmes FA, Valero V, Buzdar AU et al. Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hr infusion in patients (pt) with metastatic breast cancer (MBC): the long & short of it. Proc Am Soc Clin Oncol 1998;17:110a.
13. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-1805.
14. Reichman BS, Seidman AD, Crown JP et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-1951.
15. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-1014.
16. Hortobagyi GN, Holmes FA. Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 1996;23(suppl 1):4-9.
17. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer. High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
18. Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87:1169-1175.
19. Vici P, Conti F, Di Lauro L et al. Paclitaxel (P) in anthracycline-resistant breast cancer (BC) patients. Proc Am Soc Clin Oncol 1997;16:196a.
20. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC et al., eds. Breast Diseases. Philadelphia: J.B. Lippincott Company, 1991:604-665.